From the Heart: Discover Taiwan’s 19 Hot Spring Regions and Embark on Asia’s Most Restorative Mountain and Coastal Spa Journey
Lithosphere Reduces Blockchain Fragmentation Through MultX Interoperability Engine
Solutionz Group Announces Launch of Growth Multiplier Category Framework and Establishment of G-Squared Consortia
Richard Roth’s Media Launches Trust-Driven Performance Media System for Banks, Healthcare, and Legal Services Firms
Northwyn Wellness Group Announces Participation in the 2026 Bloom Burton & Co. Healthcare Investor Conference
SAN DIEGO–(BUSINESS WIRE)–$GNRC #GNRC—The Class: Robbins LLP reminds investors that a shareholder filed a class…
TOKYO, Dec 12, 2022 – (JCN Newswire) – Fujitsu today announced that it joined a…
– Data Suggest Long-term Treatment with PYRUKYND® in Adults with PK Deficiency is Associated with…
HONG KONG, Dec 12, 2022 – (ACN Newswire) – InvesTech Holdings Limited (“InvesTech Holdings”; together…
– 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week…
Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR T cells control CD19+ tumor cells in fully immunocompetent…
Media Release COPENHAGEN, Denmark; December 11, 2022 Epcoritamab featured in multiple data disclosures, including four…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR…
RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet…
Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC),…
First Preclinical Data for IGM-2644 and IGM-2537 Featured in Poster Presentations MOUNTAIN VIEW, Calif., Dec….
Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients…
A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models…
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) — Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in…
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1…
“Austin Accident Lawyer” Andrew Traub shares how his firm has helped their clients get past…
Company Provides Comprehensive Clinical Update from Phase 1/2 Trial Tuspetinib Continues to Deliver Single Agent…
– ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate…
The HAVEN 7 study was designed to further confirm the benefit of preventative treatment (prophylaxis)…
The phase III COMMODORE 3 study of crovalimab met primary endpoints of transfusion avoidance and…